25 XP   0   0   10

Regeneus Ltd
Buy, Hold or Sell?

Let's analyse Regeneus together

PenkeI guess you are interested in Regeneus Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Regeneus Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Regeneus Ltd

I send you an email if I find something interesting about Regeneus Ltd.

Quick analysis of Regeneus (30 sec.)










What can you expect buying and holding a share of Regeneus? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$-0.01
Expected worth in 1 year
A$-0.04
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
A$-0.04
Return On Investment
-471.5%

For what price can you sell your share?

Current Price per Share
A$0.01
Expected price per share
A$0.007 - A$0.02
How sure are you?
50%

1. Valuation of Regeneus (5 min.)




Live pricePrice per Share (EOD)

A$0.01

Intrinsic Value Per Share

A$0.03 - A$0.09

Total Value Per Share

A$0.02 - A$0.08

2. Growth of Regeneus (5 min.)




Is Regeneus growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.1m$690.1k-$1.8m-159.2%

How much money is Regeneus making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$2.8m$1.7m159.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Regeneus (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#884 / 1014

Most Revenue
#833 / 1014

Most Profit
#245 / 1014

Most Efficient
#277 / 1014

What can you expect buying and holding a share of Regeneus? (5 min.)

Welcome investor! Regeneus's management wants to use your money to grow the business. In return you get a share of Regeneus.

What can you expect buying and holding a share of Regeneus?

First you should know what it really means to hold a share of Regeneus. And how you can make/lose money.

Speculation

The Price per Share of Regeneus is A$0.008. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Regeneus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Regeneus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$-0.01. Based on the TTM, the Book Value Change Per Share is A$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Regeneus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-44.2%0.00-44.2%-0.01-112.9%0.00-54.1%-0.01-78.4%
Usd Book Value Change Per Share-0.01-75.7%-0.01-75.7%-0.01-80.4%0.00-24.8%0.00-45.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-75.7%-0.01-75.7%-0.01-80.4%0.00-24.8%0.00-45.9%
Usd Price Per Share0.00-0.00-0.04-0.04-0.08-
Price to Earnings Ratio-1.27--1.27--4.34--4.34--5.09-
Price-to-Total Gains Ratio-0.74--0.74--6.09--0.17--127.55-
Price to Book Ratio-1.18--1.18-17.39--29.22--10.22-
Price-to-Total Gains Ratio-0.74--0.74--6.09--0.17--127.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0051368
Number of shares194673
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (194673 shares)-1,178.77-386.43
Gains per Year (194673 shares)-4,715.06-1,545.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4715-47250-1546-1556
20-9430-94400-3091-3102
30-14145-141550-4637-4648
40-18860-188700-6183-6194
50-23575-235850-7729-7740
60-28290-283000-9274-9286
70-33005-330150-10820-10832
80-37720-377300-12366-12378
90-42436-424450-13912-13924
100-47151-471600-15457-15470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%5.09.02.031.3%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.07.00.030.0%7.09.00.043.8%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%4.00.012.025.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.07.00.030.0%7.09.00.043.8%

Fundamentals of Regeneus

About Regeneus Ltd

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

Fundamental data was last updated by Penke on 2024-04-04 23:45:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Regeneus Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Regeneus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Regeneus to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Regeneus Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-4,629.0%+4,629.0%
5Y-4,629.0%10Y-2,533.6%-2,095.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM--211.9%+211.9%
YOY--277.7%+277.7%
5Y-4,629.0%-432.9%-4,196.1%
10Y-2,533.6%-599.3%-1,934.3%
1.1.2. Return on Assets

Shows how efficient Regeneus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Regeneus to the Biotechnology industry mean.
  • -236.1% Return on Assets means that Regeneus generated $-2.36 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Regeneus Ltd:

  • The MRQ is -236.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -236.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-236.1%TTM-236.1%0.0%
TTM-236.1%YOY-171.5%-64.6%
TTM-236.1%5Y-143.3%-92.8%
5Y-143.3%10Y-98.7%-44.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-236.1%-13.3%-222.8%
TTM-236.1%-12.7%-223.4%
YOY-171.5%-11.8%-159.7%
5Y-143.3%-14.0%-129.3%
10Y-98.7%-15.9%-82.8%
1.1.3. Return on Equity

Shows how efficient Regeneus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Regeneus to the Biotechnology industry mean.
  • 0.0% Return on Equity means Regeneus generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Regeneus Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-407.7%+407.7%
TTM-5Y-71.2%+71.2%
5Y-71.2%10Y-73.8%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.0%+16.0%
YOY-407.7%-15.1%-392.6%
5Y-71.2%-19.7%-51.5%
10Y-73.8%-20.5%-53.3%

1.2. Operating Efficiency of Regeneus Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Regeneus is operating .

  • Measures how much profit Regeneus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Regeneus to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Regeneus Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-4,704.3%+4,704.3%
5Y-4,704.3%10Y-2,567.0%-2,137.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM--224.4%+224.4%
YOY--288.3%+288.3%
5Y-4,704.3%-479.5%-4,224.8%
10Y-2,567.0%-625.2%-1,941.8%
1.2.2. Operating Ratio

Measures how efficient Regeneus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Regeneus Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y55.502-55.502
5Y55.50210Y31.806+23.696
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM-3.266-3.266
YOY-3.783-3.783
5Y55.5025.657+49.845
10Y31.8067.783+24.023

1.3. Liquidity of Regeneus Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Regeneus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.28 means the company has $0.28 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Regeneus Ltd:

  • The MRQ is 0.282. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.282. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.282TTM0.2820.000
TTM0.282YOY0.533-0.251
TTM0.2825Y1.447-1.165
5Y1.44710Y3.235-1.788
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2823.905-3.623
TTM0.2824.212-3.930
YOY0.5335.337-4.804
5Y1.4476.062-4.615
10Y3.2356.401-3.166
1.3.2. Quick Ratio

Measures if Regeneus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Regeneus to the Biotechnology industry mean.
  • A Quick Ratio of 0.27 means the company can pay off $0.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Regeneus Ltd:

  • The MRQ is 0.271. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.271. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.271TTM0.2710.000
TTM0.271YOY0.536-0.265
TTM0.2715Y1.539-1.268
5Y1.53910Y2.012-0.473
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2713.572-3.301
TTM0.2714.001-3.730
YOY0.5365.364-4.828
5Y1.5396.009-4.470
10Y2.0126.287-4.275

1.4. Solvency of Regeneus Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Regeneus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Regeneus to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.54 means that Regeneus assets are financed with 354.0% credit (debt) and the remaining percentage (100% - 354.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Regeneus Ltd:

  • The MRQ is 3.540. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 3.540. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.540TTM3.5400.000
TTM3.540YOY0.579+2.961
TTM3.5405Y1.836+1.704
5Y1.83610Y1.023+0.813
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5400.336+3.204
TTM3.5400.334+3.206
YOY0.5790.271+0.308
5Y1.8360.366+1.470
10Y1.0230.389+0.634
1.4.2. Debt to Equity Ratio

Measures if Regeneus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Regeneus to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Regeneus Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.377-1.377
TTM-5Y0.486-0.486
5Y0.48610Y0.390+0.096
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.397-0.397
YOY1.3770.341+1.036
5Y0.4860.432+0.054
10Y0.3900.465-0.075

2. Market Valuation of Regeneus Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Regeneus generates.

  • Above 15 is considered overpriced but always compare Regeneus to the Biotechnology industry mean.
  • A PE ratio of -1.27 means the investor is paying $-1.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Regeneus Ltd:

  • The EOD is -1.453. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.272. Based on the earnings, the company is expensive. -2
  • The TTM is -1.272. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.453MRQ-1.272-0.182
MRQ-1.272TTM-1.2720.000
TTM-1.272YOY-4.337+3.066
TTM-1.2725Y-4.336+3.065
5Y-4.33610Y-5.089+0.752
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.453-2.262+0.809
MRQ-1.272-2.599+1.327
TTM-1.272-2.674+1.402
YOY-4.337-4.133-0.204
5Y-4.336-6.258+1.922
10Y-5.089-6.171+1.082
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Regeneus Ltd:

  • The EOD is -3.712. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.248. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.248. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.712MRQ-3.248-0.464
MRQ-3.248TTM-3.2480.000
TTM-3.248YOY-4.282+1.034
TTM-3.2485Y-670.203+666.955
5Y-670.20310Y-338.721-331.482
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.712-2.913-0.799
MRQ-3.248-3.275+0.027
TTM-3.248-3.508+0.260
YOY-4.282-5.620+1.338
5Y-670.203-8.306-661.897
10Y-338.721-8.854-329.867
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Regeneus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.18 means the investor is paying $-1.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Regeneus Ltd:

  • The EOD is -1.351. Based on the equity, the company is expensive. -2
  • The MRQ is -1.182. Based on the equity, the company is expensive. -2
  • The TTM is -1.182. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.351MRQ-1.182-0.169
MRQ-1.182TTM-1.1820.000
TTM-1.182YOY17.392-18.574
TTM-1.1825Y-29.220+28.038
5Y-29.22010Y-10.223-18.997
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.3511.858-3.209
MRQ-1.1822.090-3.272
TTM-1.1822.091-3.273
YOY17.3922.866+14.526
5Y-29.2203.488-32.708
10Y-10.2233.836-14.059
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Regeneus Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Regeneus Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.009-0.0090%-0.010+6%-0.003-67%-0.006-39%
Book Value Per Share---0.006-0.0060%0.004-269%-0.002-66%0.010-162%
Current Ratio--0.2820.2820%0.533-47%1.447-80%3.235-91%
Debt To Asset Ratio--3.5403.5400%0.579+511%1.836+93%1.023+246%
Debt To Equity Ratio----0%1.377-100%0.486-100%0.390-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.006-0.0060%-0.014+155%-0.007+22%-0.010+78%
Free Cash Flow Per Share---0.002-0.0020%-0.014+561%-0.003+38%-0.007+227%
Free Cash Flow To Equity Per Share--0.0010.0010%-0.015+1845%0.001-38%0.001-22%
Gross Profit Margin--1.4121.4120%1.000+41%1.106+28%1.112+27%
Intrinsic Value_10Y_max--0.085--------
Intrinsic Value_10Y_min--0.030--------
Intrinsic Value_1Y_max--0.000--------
Intrinsic Value_1Y_min---0.001--------
Intrinsic Value_3Y_max--0.006--------
Intrinsic Value_3Y_min---0.001--------
Intrinsic Value_5Y_max--0.020--------
Intrinsic Value_5Y_min--0.004--------
Market Cap2451495.936+13%2145058.9442145058.9440%18692656.512-89%18085911.268-88%36000217.820-94%
Net Profit Margin----0%-0%-46.2900%-25.3360%
Operating Margin----0%-0%-47.0430%-25.6700%
Operating Ratio----0%-0%55.502-100%31.806-100%
Pb Ratio-1.351-14%-1.182-1.1820%17.392-107%-29.220+2372%-10.223+765%
Pe Ratio-1.453-14%-1.272-1.2720%-4.337+241%-4.336+241%-5.089+300%
Price Per Share0.008+13%0.0070.0070%0.061-89%0.059-88%0.117-94%
Price To Free Cash Flow Ratio-3.712-14%-3.248-3.2480%-4.282+32%-670.203+20536%-338.721+10329%
Price To Total Gains Ratio-0.848-14%-0.742-0.7420%-6.087+720%-0.167-78%-127.548+17083%
Quick Ratio--0.2710.2710%0.536-49%1.539-82%2.012-87%
Return On Assets---2.361-2.3610%-1.715-27%-1.433-39%-0.987-58%
Return On Equity----0%-4.0770%-0.7120%-0.7380%
Total Gains Per Share---0.009-0.0090%-0.010+6%-0.003-67%-0.006-39%
Usd Book Value---1165384.532-1165384.5320%690123.301-269%-399663.459-66%1879710.251-162%
Usd Book Value Change Per Share---0.006-0.0060%-0.006+6%-0.002-67%-0.004-39%
Usd Book Value Per Share---0.004-0.0040%0.002-269%-0.001-66%0.006-162%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.0040%-0.009+155%-0.004+22%-0.006+78%
Usd Free Cash Flow---424083.934-424083.9340%-2803339.253+561%-586392.175+38%-1385409.471+227%
Usd Free Cash Flow Per Share---0.001-0.0010%-0.009+561%-0.002+38%-0.005+227%
Usd Free Cash Flow To Equity Per Share--0.0010.0010%-0.009+1845%0.001-38%0.001-22%
Usd Market Cap1574105.541+13%1377342.3481377342.3480%12002554.746-89%11612963.625-88%23115739.862-94%
Usd Price Per Share0.005+13%0.0040.0040%0.039-89%0.038-88%0.075-94%
Usd Profit---1083147.574-1083147.5740%-2813930.051+160%-1734492.787+60%-2126893.774+96%
Usd Revenue----0%-0%1124374.632-100%1533255.757-100%
Usd Total Gains Per Share---0.006-0.0060%-0.006+6%-0.002-67%-0.004-39%
 EOD+6 -2MRQTTM+0 -0YOY+17 -125Y+10 -2110Y+11 -20

4.2. Fundamental Score

Let's check the fundamental score of Regeneus Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.453
Price to Book Ratio (EOD)Between0-1-1.351
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.271
Current Ratio (MRQ)Greater than10.282
Debt to Asset Ratio (MRQ)Less than13.540
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.361
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Regeneus Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.115
Ma 20Greater thanMa 500.008
Ma 50Greater thanMa 1000.007
Ma 100Greater thanMa 2000.006
OpenGreater thanClose0.009
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets714
Total Liabilities2,529
Total Stockholder Equity-1,815
 As reported
Total Liabilities 2,529
Total Stockholder Equity+ -1,815
Total Assets = 714

Assets

Total Assets714
Total Current Assets714
Long-term Assets1
Total Current Assets
Cash And Cash Equivalents 303
Net Receivables 383
Other Current Assets 28
Total Current Assets  (as reported)714
Total Current Assets  (calculated)714
+/-0
Long-term Assets
Property Plant Equipment 1
Long-term Assets  (as reported)1
Long-term Assets  (calculated)1
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,529
Long-term Liabilities0
Total Stockholder Equity-1,815
Total Current Liabilities
Short-term Debt 1,947
Short Long Term Debt 1,947
Accounts payable 501
Other Current Liabilities 81
Total Current Liabilities  (as reported)2,529
Total Current Liabilities  (calculated)4,476
+/- 1,947
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock38,619
Retained Earnings -42,277
Other Stockholders Equity 1,843
Total Stockholder Equity (as reported)-1,815
Total Stockholder Equity (calculated)-1,815
+/-0
Other
Capital Stock38,619
Cash and Short Term Investments 303
Common Stock Shares Outstanding 306,437
Liabilities and Stockholders Equity 714
Net Debt 1,644
Net Invested Capital 132
Net Tangible Assets -125
Net Working Capital -1,816
Property Plant and Equipment Gross 1
Short Long Term Debt Total 1,947



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302010-06-302002-06-302001-06-302000-06-301999-06-30
> Total Assets 
281,417
289,365
325,409
50,204
1,821
16,733
10,259
9,579
5,935
9,165
4,983
2,542
3,564
8,510
2,555
714
7142,5558,5103,5642,5424,9839,1655,9359,57910,25916,7331,82150,204325,409289,365281,417
   > Total Current Assets 
59,160
61,816
78,944
33,991
0
16,095
7,089
7,128
3,503
8,261
4,313
2,385
3,484
6,727
787
714
7147876,7273,4842,3854,3138,2613,5037,1287,08916,095033,99178,94461,81659,160
       Cash And Cash Equivalents 
42,577
39,104
31,674
33,483
0
14,175
2,507
3,013
529
4,135
1,092
255
982
3,793
95
303
303953,7939822551,0924,1355293,0132,50714,175033,48331,67439,10442,577
       Short-term Investments 
0
0
0
0
0
123
278
0
0
0
0
596
570
570
69
0
069570570596000027812300000
       Net Receivables 
4,200
5,495
9,909
378
533
1,522
230
158
126
1,317
896
647
1,896
2,910
558
383
3835582,9101,8966478961,3171261582301,5225333789,9095,4954,200
       Inventory 
10,096
15,945
35,240
0
26
192
206
99
30
22
15
9
12
0
40
0
04001291522309920619226035,24015,94510,096
   > Long-term Assets 
0
0
0
0
0
638
3,170
2,451
2,432
904
670
157
80
1,784
1,767
1
11,7671,784801576709042,4322,4513,17063800000
       Property Plant Equipment 
184,231
188,138
209,953
1,872
72
589
1,362
892
802
610
417
153
80
34
17
1
11734801534176108028921,362589721,872209,953188,138184,231
       Long Term Investments 
1,656
1,728
6,136
12,525
0
0
0
0
0
78
41
4
0
0
1,750
0
01,75000441780000012,5256,1361,7281,656
       Intangible Assets 
0
0
0
0
0
49
30
26
11
6
2
0
0
0
0
0
00000261126304900000
       Long-term Assets Other 
0
0
0
0
0
0
1,236
1,323
1,619
210
210
157
-1,225
-1,750
0
0
00-1,750-1,2251572102101,6191,3231,236000000
> Total Liabilities 
150,858
128,271
129,200
9,666
450
1,029
1,951
1,307
1,150
1,065
2,061
8,928
3,695
4,365
1,480
2,529
2,5291,4804,3653,6958,9282,0611,0651,1501,3071,9511,0294509,666129,200128,271150,858
   > Total Current Liabilities 
51,405
47,176
63,048
9,544
450
1,029
1,698
1,260
1,006
876
1,819
8,753
3,633
1,297
1,477
2,529
2,5291,4771,2973,6338,7531,8198761,0061,2601,6981,0294509,54463,04847,17651,405
       Short-term Debt 
121,506
41,764
29,528
0
0
0
489
253
0
0
1,000
3,780
1,105
5
1,006
1,947
1,9471,00651,1053,7801,0000025348900029,52841,764121,506
       Short Long Term Debt 
121,506
41,764
29,528
0
0
0
742
253
0
0
1,000
3,780
1,100
0
1,000
1,947
1,9471,00001,1003,7801,0000025374200029,52841,764121,506
       Accounts payable 
10,265
6,568
0
0
284
628
435
453
539
350
372
1,056
556
872
158
501
5011588725561,056372350539453435628284006,56810,265
       Other Current Liabilities 
8,348
23,826
42,178
2,798
166
95
654
438
466
508
446
7,344
1,440
419
313
81
813134191,4407,344446508466438654951662,79842,17823,8268,348
   > Long-term Liabilities 
0
0
0
0
0
0
253
48
144
189
243
175
63
3,068
3
0
033,0686317524318914448253000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
14
9
3
0
03914000000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
19
14
8
0
081419000000000000
       Deferred Long Term Liability 
0
1,327
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,3270
> Total Stockholder Equity
127,536
155,431
182,737
39,634
1,371
15,704
8,308
8,272
4,785
8,100
2,922
-6,386
-131
4,145
1,075
-1,815
-1,8151,0754,145-131-6,3862,9228,1004,7858,2728,30815,7041,37139,634182,737155,431127,536
   Common Stock
87,576
83,670
82,034
30,762
2,490
24,978
24,909
31,077
31,077
31,077
31,077
31,077
38,156
38,259
38,619
38,619
38,61938,61938,25938,15631,07731,07731,07731,07731,07724,90924,9782,49030,76282,03483,67087,576
   Retained Earnings 
40,339
67,756
83,872
8,457
0
-10,010
-18,792
-25,296
-27,917
-24,630
-29,775
-37,875
-38,718
-34,649
-38,951
-42,277
-42,277-38,951-34,649-38,718-37,875-29,775-24,630-27,917-25,296-18,792-10,01008,45783,87267,75640,339
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
-379
4,005
16,831
415
0
0
2,192
2,491
1,625
1,653
1,619
412
2,229
0
1,407
1,843
1,8431,40702,2294121,6191,6531,6252,4912,1920041516,8314,005-379



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.